Ken Griffin Immuneering Corp Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.28 - $2.75 $81 - $176	-64 Reduced -0.0%	1,882,136 $2.41 Million
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $374,153 - $1.43 Million	-195,892 Reduced 9.43%	1,882,200 $5.44 Million
Q4 2023 Feb 14, 2024	BUY	$4.84 - $8.44 $56,729 - $98,925	11,721 Added 0.57%	2,078,092 $15.3 Million
Q3 2023 Nov 14, 2023	SELL	$7.21 - $10.68 $37,470 - $55,503	-5,197 Reduced 0.25%	2,066,371 $15.9 Million
Q2 2023 Aug 14, 2023	SELL	$6.49 - $13.36 $214,721 - $442,015	-33,085 Reduced 1.57%	2,071,568 $21 Million
Q1 2023 May 15, 2023	SELL	$3.78 - $10.38 $139,270 - $382,440	-36,844 Reduced 1.72%	2,104,653 $20.4 Million
Q4 2022 Feb 14, 2023	SELL	$4.09 - $15.0 $177,555 - $651,180	-43,412 Reduced 1.99%	2,141,497 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$5.0 - $14.32 $71,500 - $204,776	-14,300 Reduced 0.65%	2,184,909 $31.3 Million

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $55.4M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.